UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): ~~November~~March 1430, ~~2011~~2012

CHINA SHENGHUO PHARMACEUTICAL HOLDINGS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

001-33537	20-2903562
(Commission File Number)	(IRS Employer Identification No.)

No. 2, Jing You Road
Kunming National Economy &
Technology Developing District
People’s Republic of China 650217	N/A
(Address of Principal Executive Offices)	(Zip Code)

0086-871-728-2628

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

¨Item ~~Soliciting~~2.02. ~~material~~Results ~~pursuant~~of toOperations ~~Rule~~and ~~14a-12~~Financial ~~under the Exchange Act (17 CFR 240~~Condition.~~14a-12)~~

¨On ~~Pre-commencement~~March ~~communications~~30, ~~pursuant~~2012, toChina ~~Rule~~Shenghuo ~~14d-2~~Pharmaceutical Holdings, Inc. (bthe “Company”) ~~under~~issued a press release announcing its financial results for the ~~Exchange~~fiscal ~~Act~~year ~~(17~~ended ~~CFR~~December 31, ~~240~~2011.~~14d-2(b))~~

¨A ~~Pre-commencement~~copy ~~communications~~of ~~pursuant~~the topress ~~Rule~~release ~~13e-4(c)~~is ~~under~~being ~~the~~furnished with ~~Exchange~~this ~~Act~~Current ~~(17~~Report ~~CFR~~on ~~240.13e~~Form 8-~~4(c))~~K as Exhibit 99.1.

Item 27.0201. ~~Results~~Regulation ofFD ~~Operations and Financial Condition~~Disclosure.

OnThe ~~November~~information ~~14,~~set ~~2011,~~forth ~~China~~in ~~Shenghuo~~Item ~~Pharmaceutical Holdings, Inc~~2.02 of ~~(the~~this ~~“Company”)~~Current ~~issued~~Report aon ~~press~~Form ~~release~~8-K ~~announcing~~is ~~its~~incorporated ~~financial~~herein ~~results~~by ~~for~~reference ~~the~~in ~~third~~its ~~fiscal quarter ended September 30, 2011~~entirety.

AThe ~~copy~~information ofreported ~~the~~under ~~press~~Items ~~release~~2.02 and is7.01 ~~being~~in ~~furnished with~~ this Current Report on Form 8-K, asincluding Exhibit 99.1 attached hereto, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

~~The information contained herein and in the accompanying exhibit is being furnished pursuant to “~~Item 29.0201. ~~Results of Operations and~~ Financial ~~Condition.”~~Statements ~~The information contained herein~~ and ~~in the accompanying Exhibit 99~~Exhibits.1 shall not be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing. The information in this report, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended.

~~Item~~(d) ~~9.01. Financial Statements and~~ Exhibits.

(d) Exhibits

Exhibit

Number

Description

99.1

Press Release, dated March 30, 2012

Exhibit
Number		Description
99.1		Press Release of China Shenghuo Pharmaceutical Holdings, Inc., dated November 14, 2011

SIGNATURES

~~SIGNATURES~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CHINA SHENGHUO PHARMACEUTICAL HOLDINGS, INC.
Date: March 31, 2012
	By:	/s/ Feng Lan
		Name: Feng Lan
		Title: Chief Executive Officer and President

	CHINA SHENGHUO PHARMACEUTICAL HOLDINGS, INC.
Date: November 15, 2011
	By:	/s/ Feng Lan
		Name: Feng Lan
		Title: Chief Executive Officer and President

EXHIBIT INDEX

EXHIBIT INDEX

Exhibit

Number

Description

99.1

Press Release, dated March 30, 2012

Exhibit
Number		Description
99.1		Press Release of China Shenghuo Pharmaceutical Holdings, Inc., dated November 14, 2011

Filing Compare · China Shenghuo Pharmaceutical Holdings Inc